Prognostic significance of minimal residual disease in high risk B-ALL: A report from Children's Oncology Group study AALL0232

Blood

Volumn 126, Issue 8, 2015, Pages 964-971

  Borowitz, Michael J ^a   Wood, Brent L ^b   Devidas, Meenakshi ^c   Loh, Mignon L ^d   Raetz, Elizabeth A ^e   Salzer, Wanda L ^f   Nachman, James B ^g   Carroll, Andrew J ^h   Heerema, Nyla A ⁱ   Gastier Foster, Julie M ^j   Willman, Cheryl L ^k   Dai, Yunfeng ^c   Winick, Naomi J ^l   Hunger, Stephen P ^m   Carroll, William L ⁿ   Larsen, Eric ^o  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^j NATIONWIDE CHILDREN S HOSPITAL   (United States)

^k UNIVERSITY OF NEW MEXICO   (United States)

^l UNIVERSITY OF TEXAS AT DALLAS   (United States)

^m CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁿ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o Maine Children's Cancer Program Scarborough   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; DAUNORUBICIN; DEXAMETHASONE; METHOTREXATE; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; ASPARAGINASE; FOLINIC ACID; MACROGOL DERIVATIVE;

ADOLESCENT; ARTICLE; B CELL LEUKEMIA; CANCER PATIENT; CANCER PROGNOSIS; CHILD; CHILDHOOD LEUKEMIA; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; MAINTENANCE CHEMOTHERAPY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; DOSE RESPONSE; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MAINTENANCE CHEMOTHERAPY; MALE; METHOTREXATE; NEOPLASM, RESIDUAL; POLYETHYLENE GLYCOLS; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84940063254     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-633685     Document Type: Article

References (40)

1. Borowitz MJ, Devidas M, Hunger SP, et al Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111(12):5477-5485.
2. Cazzaniga G, Gaipa G, Rossi V, Biondi A. Minimal residual disease as a surrogate marker for risk assignment to ALL patients. Rev Clin Exp Hematol. 2003;7(3):292-323.
3. Conter V, Aricò M, Basso G, et al; Associazione Italiana di Ematologia ed Oncologia Pediatrica. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):255-264.
4. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96(8):2691-2696.
5. Dworzak MN, Fröschl G, Printz D, et al Austrian Berlin-Frankfurt-Münster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99(6):1952-1958.
6. Panzer-Grümayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000;95(3):790-794.
7. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-3214.
8. Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002;100(1):52-58.
9. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730-2741.
10. Vora A, Goulden N, Mitchell C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014;15(8):809-818.
11. Yeoh AE, Ariffin H, Chai EL, et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol. 2012;30(19):2384-2392.
12. Yamaji K, Okamoto T, Yokota S, et al Japanese Childhood Cancer Leukemia Study Group. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer. 2010;55(7):1287-1295.
13. Escherich G, Horstmann MA, Zimmermann M, Janka-Schaub GE; COALL study group. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. Leukemia. 2010;24(2):298-308.
14. Schmiegelow K, Forestier E, Hellebostad M, et al Nordic Society of Paediatric Haematology and Oncology. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):345-354.
15. Marshall GM, Dalla Pozza L, Sutton R, et al. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia. 2013;27(7):1497-1503.
16. Weir EG, Cowan K, LeBeau P, Borowitz MJ. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia. 1999;13(4):558-567.
17. Dworzak MN, Fritsch G, Panzer-Grümayer ER, Mann G, Gadner H. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance. Leuk Lymphoma. 2000;38(3-4):295-308.
18. Borowitz MJ, Pullen DJ, Shuster JJ, et al; Children's Oncology Group study. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. Leukemia. 2003;17(8):1566-1572.
19. Larsen EC, Salzer WL, Devidas M, et al. Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): a report from the Children's Oncology Group Study AALL0232 [abstract]. J Clin Oncol. 2011;29(suppl 15). Abstract 3.
20. Winick NL, Salzer WL, Devidas M, et al. Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high-risk acute lymphoblastic leukemia (HR-ALL): a report from the Children's Oncology Group Study AALL0232. J Clin Oncol. 2011;29(suppl 15). Abstract 9504.
21. Bhojwani D, Kang H, Moskowitz NP, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2006;108(2):711-717.
22. Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group Study [corrected]. J Clin Oncol.2008;26(24):3971-3978.
23. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338(23):1663-1671.
24. Eckert C, Henze G, Seeger K, et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol. 2013;31(21):2736-2742.
25. Gökbuget N, Stanze D, Beck J, et al German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032-2041.
26. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer program. Leukemia. 2003;17(12):2318-2357.
27. Pongers-Willemse MJ, Seriu T, Stolz F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13(1):110-118.
28. Salari F, Shahjahani M, Shahrabi S, Saki N. Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches. Med Oncol. 2014;31(11):266.
29. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17(6):1013-1034.
30. van der Velden VH, Panzer-Grümayer ER, Cazzaniga G, et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multicenter setting. Leukemia. 2007;21(4):706-713.
31. Brüggemann M, Schrauder A, Raff T, et al European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL); International Berlin-Frankfurt-Münster Study Group (I-BFM-SG). Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia. 2010;24(3):521-535.
32. Dworzak MN, Gaipa G, Ratei R, et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. Cytometry B Clin Cytom. 2008;74(6):331-340.
33. Björklund E, Matinlauri I, Tierens A, et al. Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment. J Pediatr Hematol Oncol. 2009;31(6):406-415.
34. Fossat C, Roussel M, Arnoux I, et al French Multicenter Study Groups for Pediatric and Adult ALL. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: a French multicenter study. Cytometry B Clin Cytom. 2015;88(1):21-29.
35. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120(6):1165-1174.
36. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-2498.
37. Chevallier P, Bodet-Milin C, Robillard N, et al. BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle. Eur J Haematol. 2013;91(6):552-556.
38. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
39. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009;27(31):5175-5181.
40. Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376(9757):2009-2017.